Compare GEHC & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEHC | NTRA |
|---|---|---|
| Founded | 1892 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8B | 32.9B |
| IPO Year | 2022 | 2015 |
| Metric | GEHC | NTRA |
|---|---|---|
| Price | $81.10 | $203.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $91.17 | ★ $260.14 |
| AVG Volume (30 Days) | ★ 3.2M | 1.1M |
| Earning Date | 05-06-2026 | 05-19-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | ★ 4.84 | 0.65 |
| EPS | ★ 4.55 | N/A |
| Revenue | ★ $20,625,000,000.00 | $210,939,000.00 |
| Revenue This Year | $7.15 | $15.22 |
| Revenue Next Year | $4.53 | $18.52 |
| P/E Ratio | $17.68 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $57.65 | $125.38 |
| 52 Week High | $89.77 | $256.36 |
| Indicator | GEHC | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 37.36 |
| Support Level | $77.55 | $195.46 |
| Resistance Level | $85.76 | $251.09 |
| Average True Range (ATR) | 2.28 | 7.79 |
| MACD | 0.19 | 0.14 |
| Stochastic Oscillator | 48.71 | 27.86 |
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.